Year 2015, Volume 45, Issue 6, Pages 1306 - 1311 2015-12-04

Osteoprotegerin as a marker of atherosclerosis in type 1 and type 2 diabetic patients
Osteoprotegerin as a marker of atherosclerosis in type 1 and type 2 diabetic patients

ÇİĞDEM ALKAÇ [1] , BURAK ALKAÇ [2] , FERAY AKBAŞ [3] , HALE ARAL [4] , YEŞİM KARAGÖZ [5] , ESMA GÜLDAL ALTUNOĞLU [6]

224 468

Background/aim: The aim of this study was to investigate the availability of osteoprotegerin (OPG) as a marker of atherosclerosis and compare serum OPG levels with ankle-brachial index (ABI) in diabetic patients. Materials and methods: A total of 31 type 1 and 31 type 2 diabetic patients without macrovascular complications and 20 healthy volunteers were included. Serum OPG levels and ABI were measured. Results: The duration of diabetes was significantly higher in type 1 diabetics than in type 2, although there was no significant difference between mean HbA1c levels. There was a weak and inverse correlation between OPG and atherosclerosis in type 1 diabetics only (P = 0.046, r = -0.360). There was a weak, positive correlation between ABI and HbA1c in all participant groups (P = 0.047, r = 0.220), and a weak-medium correlation in type 2 diabetics (P = 0.021, r = 0.414). After the adjustment of OPG levels to atherosclerosis risk factors, only the age factor was found to be effective on OPG. Conclusion: The inverse correlation of serum OPG with atherosclerosis in type 1 diabetics suggests that atherosclerosis may be related to increased duration of diabetes. Since the study participants did not show macrovascular complications, future prospective studies on the development of diabetic complications and correlation with OPG might give further information about the availability of OPG as a marker of atherosclerosis.
Background/aim: The aim of this study was to investigate the availability of osteoprotegerin (OPG) as a marker of atherosclerosis and compare serum OPG levels with ankle-brachial index (ABI) in diabetic patients. Materials and methods: A total of 31 type 1 and 31 type 2 diabetic patients without macrovascular complications and 20 healthy volunteers were included. Serum OPG levels and ABI were measured. Results: The duration of diabetes was significantly higher in type 1 diabetics than in type 2, although there was no significant difference between mean HbA1c levels. There was a weak and inverse correlation between OPG and atherosclerosis in type 1 diabetics only (P = 0.046, r = -0.360). There was a weak, positive correlation between ABI and HbA1c in all participant groups (P = 0.047, r = 0.220), and a weak-medium correlation in type 2 diabetics (P = 0.021, r = 0.414). After the adjustment of OPG levels to atherosclerosis risk factors, only the age factor was found to be effective on OPG. Conclusion: The inverse correlation of serum OPG with atherosclerosis in type 1 diabetics suggests that atherosclerosis may be related to increased duration of diabetes. Since the study participants did not show macrovascular complications, future prospective studies on the development of diabetic complications and correlation with OPG might give further information about the availability of OPG as a marker of atherosclerosis.
  • Satman I, Yılmaz T, Şengül A, Salman S, Salman F, Uygur S, Bastar I, Tütüncü Y, Sargin M, Dinççag N et al. Population- based study of diabetes and risk characteristics in Turkey: results of the Turkish diabetes epidemiology study (TURDEP). Diabetes Care 2002; 25: 1551–1556.
  • Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337–342. 3. Brändström H, Stiger F, Lind L, Kahan T, Melhus H, Kindmark A. A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function. Biochem Bioph Res Co 2002; 293: 13–17.
  • Abbott RD, Rodriguez BL, Petrovitch H, Yano K, Schatz IJ, Popper JS, Masaki KH, Ross GW, Curb JD. Ankle brachial blood pressure in elderly men and the risk of stroke: the Honolulu Heart Program. J Clin Epidemiol 2001; 54: 973–978. 5. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. New Engl J Med 1992; 326: 381–386.
  • Ostchega Y, Paulose-Ram R, Dillon CF, Gu Q, Hughes JP. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999–2004. J Am Geriatr Soc 2007; 55: 583–589.
  • Resnick HE, Lindsay RS, McDermott MM, Devereux RB, Jones KL, Fabsitz RR, Howard BV. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation 2004; 109: 733– 739.
  • Weatherley BD, Nelson JJ, Heiss G, Chambless LE, Sharrett AR, Nieto FJ, Folsom AR, Rosamond WD. The association of the ankle-brachial index with incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study 1987– 2001. BMC Cardiovasc Disord 2007; 7: 3–13.
  • Wild SH, Byrne CD, Smith FB, Lee AJ, Fowkes FGR. Low ankle-brachial pressure index predicts increased risk of cardiovascular disease independent of the metabolic syndrome and conventional cardiovascular risk factors in the Edinburgh Artery Study. Diabetes Care 2006; 29: 637–642.
  • Zheng ZJ, Sharrett AR, Chambless LE, Rosamond WD, Nieto FJ, Sheps DS, Dobs A, Evans GW, Heiss G. Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis 1997; 131: 115–125.
  • Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of U.S. population, 1971– 1993. Diabetes Care 1998; 21: 1138–1145.
  • Koistinen MJ. Prevalence of asymptomatic myocardial ischaemia in diabetic subjects. Brit Med J 1990; 301: 92–95.
  • Milan Study on Atherosclerosis and Diabetes (MiSAD) Group. Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in non-insulin dependent diabetes mellitus. Am J Cardiol 1997; 79: 134–139.
  • Ishii H, Kumada Y, Takahashi H, Toriyama T, Aoyama T, Tanaka M, Yoshikawa D, Hayashi M, Kasuga H, Yasuda Y et al. Impact of diabetes and glycaemic control on peripheral artery disease in Japanese patients with end-stage renal disease: long- term follow-up study from the beginning of haemodialysis. Diabetologia 2012; 55: 1304–1309.
  • Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106: 1192–1194.
  • Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocr Metab 2003; 88: 1024–1028.
  • Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures and mortality in elderly women. J Clin Endocr Metab 2001; 86: 631–637.
  • Reinhard H, Lajer M, Gall MA, Tarnow L, Parving HH, Rasmussen LM, Rossing P. Osteoprotegerin and mortality in type 2 diabetic patients. Diabetes Care 2010; 33: 2561–2566.
  • Mogelvang R, Pedersen SH, Flyvbjerg A, Bjerre M, Iversen AZ, Galatius S, Frystyk J, Jensen JS. Comparison of osteoprotegerin to traditional atherosclerotic risk factors and high-sensitivity C-reactive protein for diagnosis of atherosclerosis. Am J Cardiol 2012; 109: 515–520.
  • Altinova AE, Toruner F, Akturk M, Bukan N, Yetkin I, Cakir N, Arslan M. Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes. Scand J Clin Lab Inv 2011; 71: 340–343.
  • Guzel S, Seven A, Kocaoglu A, Ilk B, Guzel EC, Saracoglu GV, Celebi A. Osteoprotegerin, leptin and IL-6: association with silent myocardial ischemia in type 2 diabetes mellitus. Diabetes Vasc Dis Re 2013; 10: 25–31.
  • Allison MA, Hiatt WR, Hirsch AT, Coll JR, Criqui MH. A high ankle-brachial index is associated with increased cardiovascular disease morbidity and lower quality of life. J Am Coll Cardiol 2008; 51: 1292–1298.
  • Avoyans V, Ho E, Denenberg JO, Ho LA, Natarjan L, Criqui MH. The association between elevated ankle systolic pressures and peripheral occlusive arterial disease in diabetic and nondiabetic subjects. J Vasc Surg 2008; 48: 1197–1203.
  • O’Sullivan EP, Ashley DT, Davenport C, Kelly J, Devlin N, Crowley R, Leahy AL, Kelly CJ, Agha A, Thompson CJ et al. Osteoprotegerin is higher in peripheral arterial disease regardless of glycaemic status. Thromb Res 2010; 126: 423–427.
  • Davenport C, Ashley DT, O’Sullivan EP, Corley BT, Fitzgerald P, Agha A, Thompson CJ, O’Gorman DJ, Smith D. Identifying coronary artery disease in men with type 2 diabetes: osteoprotegerin, pulse wave velocity, and other biomarkers of cardiovascular risk. J Hypertens 2011; 29: 2469–2475.
  • Shin JY, Shin YG, Chung CH. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care 2006; 29: 1664–1666.
  • Augoulea A, Vrachnis N, Lambrinoudaki I, Dafopoulos K, Iliodromiti Z, Daniilidis A, Varras M, Alexandrou A, Deligeoroglou E, Creatsas G. Osteoprotegerin as a marker of atherosclerosis in diabetic patients. Int J Endocrinol 2013; 2013: 182060.
  • Vik A, Mathiesen EB, Brox J, Wilsgaard T, Njİlstad I, Jİrgensen L, Hansen JB. Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromsİ Study. J Thromb Haemost 2011; 9: 638–644.
  • Wang ST, Xu JM, Wang M, Chen FL, Ding G. Increased plasma osteoprotegerin concentrations in type 1 diabetes with albuminuria. Clin Nephrol 2013; 79: 192–198.
Primary Language tr
Journal Section Articles
Authors

Author: ÇİĞDEM ALKAÇ

Author: BURAK ALKAÇ

Author: FERAY AKBAŞ

Author: HALE ARAL

Author: YEŞİM KARAGÖZ

Author: ESMA GÜLDAL ALTUNOĞLU

Dates

Publication Date: December 4, 2015

Bibtex @ { tbtkmedical149016, journal = {Turkish Journal of Medical Sciences}, issn = {1300-0144}, eissn = {1303-6165}, address = {TUBITAK}, year = {2015}, volume = {45}, pages = {1306 - 1311}, doi = {}, title = {Osteoprotegerin as a marker of atherosclerosis in type 1 and type 2 diabetic patients}, key = {cite}, author = {ALKAÇ, ÇİĞDEM and ALKAÇ, BURAK and AKBAŞ, FERAY and ARAL, HALE and KARAGÖZ, YEŞİM and ALTUNOĞLU, ESMA GÜLDAL} }
APA ALKAÇ, Ç , ALKAÇ, B , AKBAŞ, F , ARAL, H , KARAGÖZ, Y , ALTUNOĞLU, E . (2015). Osteoprotegerin as a marker of atherosclerosis in type 1 and type 2 diabetic patients. Turkish Journal of Medical Sciences, 45 (6), 1306-1311. Retrieved from http://dergipark.org.tr/tbtkmedical/issue/12391/149016
MLA ALKAÇ, Ç , ALKAÇ, B , AKBAŞ, F , ARAL, H , KARAGÖZ, Y , ALTUNOĞLU, E . "Osteoprotegerin as a marker of atherosclerosis in type 1 and type 2 diabetic patients". Turkish Journal of Medical Sciences 45 (2015): 1306-1311 <http://dergipark.org.tr/tbtkmedical/issue/12391/149016>
Chicago ALKAÇ, Ç , ALKAÇ, B , AKBAŞ, F , ARAL, H , KARAGÖZ, Y , ALTUNOĞLU, E . "Osteoprotegerin as a marker of atherosclerosis in type 1 and type 2 diabetic patients". Turkish Journal of Medical Sciences 45 (2015): 1306-1311
RIS TY - JOUR T1 - Osteoprotegerin as a marker of atherosclerosis in type 1 and type 2 diabetic patients AU - ÇİĞDEM ALKAÇ , BURAK ALKAÇ , FERAY AKBAŞ , HALE ARAL , YEŞİM KARAGÖZ , ESMA GÜLDAL ALTUNOĞLU Y1 - 2015 PY - 2015 N1 - DO - T2 - Turkish Journal of Medical Sciences JF - Journal JO - JOR SP - 1306 EP - 1311 VL - 45 IS - 6 SN - 1300-0144-1303-6165 M3 - UR - Y2 - 2019 ER -
EndNote %0 Turkish Journal of Medical Sciences Osteoprotegerin as a marker of atherosclerosis in type 1 and type 2 diabetic patients %A ÇİĞDEM ALKAÇ , BURAK ALKAÇ , FERAY AKBAŞ , HALE ARAL , YEŞİM KARAGÖZ , ESMA GÜLDAL ALTUNOĞLU %T Osteoprotegerin as a marker of atherosclerosis in type 1 and type 2 diabetic patients %D 2015 %J Turkish Journal of Medical Sciences %P 1300-0144-1303-6165 %V 45 %N 6 %R %U
ISNAD ALKAÇ, ÇİĞDEM , ALKAÇ, BURAK , AKBAŞ, FERAY , ARAL, HALE , KARAGÖZ, YEŞİM , ALTUNOĞLU, ESMA GÜLDAL . "Osteoprotegerin as a marker of atherosclerosis in type 1 and type 2 diabetic patients". Turkish Journal of Medical Sciences 45 / 6 (December 2015): 1306-1311.
AMA ALKAÇ Ç , ALKAÇ B , AKBAŞ F , ARAL H , KARAGÖZ Y , ALTUNOĞLU E . Osteoprotegerin as a marker of atherosclerosis in type 1 and type 2 diabetic patients. Turkish Journal of Medical Sciences. 2015; 45(6): 1306-1311.
Vancouver ALKAÇ Ç , ALKAÇ B , AKBAŞ F , ARAL H , KARAGÖZ Y , ALTUNOĞLU E . Osteoprotegerin as a marker of atherosclerosis in type 1 and type 2 diabetic patients. Turkish Journal of Medical Sciences. 2015; 45(6): 1311-1306.